These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 23109881)
1. Neuroprotection for stroke: current status and future perspectives. Minnerup J; Sutherland BA; Buchan AM; Kleinschnitz C Int J Mol Sci; 2012; 13(9):11753-11772. PubMed ID: 23109881 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Sutherland BA; Minnerup J; Balami JS; Arba F; Buchan AM; Kleinschnitz C Int J Stroke; 2012 Jul; 7(5):407-18. PubMed ID: 22394615 [TBL] [Abstract][Full Text] [Related]
3. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Green AR; Ashwood T Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):109-18. PubMed ID: 15857295 [TBL] [Abstract][Full Text] [Related]
4. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Philip M; Benatar M; Fisher M; Savitz SI Stroke; 2009 Feb; 40(2):577-81. PubMed ID: 19074479 [TBL] [Abstract][Full Text] [Related]
5. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Savitz SI; Fisher M Ann Neurol; 2007 May; 61(5):396-402. PubMed ID: 17420989 [TBL] [Abstract][Full Text] [Related]
6. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Savitz SI Exp Neurol; 2007 May; 205(1):20-5. PubMed ID: 17408618 [TBL] [Abstract][Full Text] [Related]
7. [Development of new stroke therapies: outlook for neuroprotective drugs]. Rogalewski A; Schäbitz WR Nervenarzt; 2008 Feb; 79(2):218-24. PubMed ID: 18214414 [TBL] [Abstract][Full Text] [Related]
8. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. Lapchak PA; Zivin JA Stroke; 2003 Aug; 34(8):2013-8. PubMed ID: 12855833 [TBL] [Abstract][Full Text] [Related]
9. Nonhuman primate models of stroke for translational neuroprotection research. Cook DJ; Tymianski M Neurotherapeutics; 2012 Apr; 9(2):371-9. PubMed ID: 22437447 [TBL] [Abstract][Full Text] [Related]
10. Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Ginsberg MD Stroke; 2007 Jun; 38(6):1967-72. PubMed ID: 17478741 [TBL] [Abstract][Full Text] [Related]
11. Emerging neuroprotective drugs for the treatment of acute ischaemic stroke. Schmidt A; Minnerup J; Kleinschnitz C Expert Opin Emerg Drugs; 2013 Jun; 18(2):109-20. PubMed ID: 23600899 [TBL] [Abstract][Full Text] [Related]
12. Quest for Quality in Translational Stroke Research-A New Dawn for Neuroprotection? Haupt M; Gerner ST; Bähr M; Doeppner TR Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628192 [TBL] [Abstract][Full Text] [Related]
13. The 2007 Feinberg lecture: a new road map for neuroprotection. Donnan GA Stroke; 2008 Jan; 39(1):242. PubMed ID: 18048866 [TBL] [Abstract][Full Text] [Related]
14. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Yamaguchi T; Sano K; Takakura K; Saito I; Shinohara Y; Asano T; Yasuhara H Stroke; 1998 Jan; 29(1):12-7. PubMed ID: 9445321 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches. Wahlgren NG; Ahmed N Cerebrovasc Dis; 2004; 17 Suppl 1():153-66. PubMed ID: 14694293 [TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. Carbone F; Teixeira PC; Braunersreuther V; Mach F; Vuilleumier N; Montecucco F Antioxid Redox Signal; 2015 Aug; 23(5):460-89. PubMed ID: 24635113 [TBL] [Abstract][Full Text] [Related]